Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyCapromab pendetide
Identification
- Name
- Capromab pendetide
- Accession Number
- DB00089 (BTD00080, BIOD00080)
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Description
Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Capromab is used to image the extent of prostate cancer.
- Protein structure
- Protein chemical formula
- Not Available
- Protein average weight
- Not Available
- Sequences
- Not Available
- Synonyms
- (111In)-Capromab pendetide
- Indium (111In) capromab pendetide
- Indium 111 Capromab Pendetide
- Indium In 111 capromab pendetide
- External IDs
- CYT-356 / Cytogen 356
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End ProstaScint Kit for the Preparation of Indium In 111 Capromab Pendetide Kit Jazz Pharmaceuticals 1996-10-28 Not applicable US 
- International/Other Brands
- ProstaScint (Cytogen Corp.)
- Categories
- UNII
- BDO5072GRX
- CAS number
- 145464-28-4
Pharmacology
- Indication
For diagnosis of prostate cancer and detection of intra-pelvic metastases.
- Structured Indications
- Pharmacodynamics
Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.
- Mechanism of action
Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Target Actions Organism AGlutamate carboxypeptidase 2 other/unknownHuman - Absorption
- Not Available
- Volume of distribution
- 4 ± 2.1 L
- Protein binding
- Not Available
- Metabolism
Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production
- Route of elimination
Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.
- Half life
- Not Available
- Clearance
- 42 +/- 22 mL/hr
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone 16-Bromoepiandrosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational 19-norandrostenedione 19-norandrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental, Illicit 5-androstenedione 5-androstenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental, Illicit Alclometasone Alclometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Aldosterone Aldosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental, Investigational Amcinonide Amcinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Androstenedione Androstenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental, Illicit Anecortave Anecortave may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational anecortave acetate anecortave acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Capromab pendetide. Approved Atamestane Atamestane may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Bacillus calmette-guerin substrain connaught live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Capromab pendetide. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Capromab pendetide. Approved BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Capromab pendetide. Investigational Beclomethasone dipropionate Beclomethasone dipropionate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Betamethasone Betamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Bicalutamide Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Budesonide Budesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Buserelin Buserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Chlormadinone Chlormadinone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental Chlorotrianisene Chlorotrianisene may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational, Withdrawn Ciclesonide Ciclesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Clobetasol Clobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Clobetasol propionate Clobetasol propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Clobetasone Clobetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Clocortolone Clocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide. Approved Conjugated estrogens Conjugated estrogens may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Cortexolone 17α-propionate Cortexolone 17α-propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Corticosterone Corticosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental Cortisone acetate Cortisone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide. Approved Cyproterone acetate Cyproterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Daidzein Daidzein may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental Danazol Danazol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Deflazacort Deflazacort may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Deslorelin Deslorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational, Vet Approved Desonide Desonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Desoximetasone Desoximetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Desoxycorticosterone acetate Desoxycorticosterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Desoxycorticosterone Pivalate Desoxycorticosterone Pivalate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental, Vet Approved Dexamethasone Dexamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Dexamethasone isonicotinate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Vet Approved Dienestrol Dienestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Diethylstilbestrol Diethylstilbestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Diflorasone Diflorasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Difluocortolone Difluocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Withdrawn Difluprednate Difluprednate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Epimestrol Epimestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental Equilenin Equilenin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental Equilin Equilin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Equol Equol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Estradiol Estradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Vet Approved Estradiol acetate Estradiol acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Vet Approved Estradiol cypionate Estradiol cypionate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Vet Approved Estradiol valerate Estradiol valerate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Vet Approved Estriol Estriol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Vet Approved Estrogens, esterified Estrogens, esterified may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Estrone Estrone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Estrone sulfate Estrone sulfate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Ethinyl Estradiol Ethinyl Estradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Fluasterone Fluasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Fludrocortisone Fludrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Flumethasone Flumethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Flunisolide Flunisolide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Fluocinolone Acetonide Fluocinolone Acetonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Vet Approved Fluocinonide Fluocinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Fluocortolone Fluocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Withdrawn Fluorometholone Fluorometholone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Fluprednidene Fluprednidene may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Withdrawn Fluprednisolone Fluprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Flurandrenolide Flurandrenolide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Flutamide Flutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Fluticasone furoate Fluticasone furoate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Fluticasone propionate Fluticasone propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Formestane Formestane may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Withdrawn G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Capromab pendetide. Investigational Genistein Genistein may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Gestrinone Gestrinone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Capromab pendetide. Investigational Goserelin Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Halcinonide Halcinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Withdrawn HE3286 HE3286 may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Capromab pendetide. Approved Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Capromab pendetide. Approved, Withdrawn Hexestrol Hexestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Withdrawn Histrelin Histrelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Capromab pendetide. Approved Hydrocortisone Hydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved INGN 201 The therapeutic efficacy of INGN 201 can be decreased when used in combination with Capromab pendetide. Investigational INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Capromab pendetide. Investigational Istaroxime Istaroxime may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide. Approved Leuprolide Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Liarozole Liarozole may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Loteprednol Loteprednol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved ME-609 ME-609 may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Medrysone Medrysone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Melengestrol Melengestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Vet Approved Mestranol Mestranol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Methallenestril Methallenestril may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental Methylprednisolone Methylprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Mometasone Mometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Moxestrol Moxestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Experimental Nafarelin Nafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved NCX 1022 NCX 1022 may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Nilutamide Nilutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Oleoyl-estrone Oleoyl-estrone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Paramethasone Paramethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Polyestradiol phosphate Polyestradiol phosphate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Prasterone Prasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational, Nutraceutical Prasterone sulfate Prasterone sulfate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Prednicarbate Prednicarbate may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Prednisolone Prednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Prednisone Prednisone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Pregnenolone Pregnenolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Experimental, Investigational Promestriene Promestriene may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational Quinestrol Quinestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Capromab pendetide. Approved, Investigational Rimexolone Rimexolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Capromab pendetide. Investigational Rotavirus Vaccine The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Capromab pendetide. Approved Rubella virus vaccine The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Capromab pendetide. Approved, Investigational Salmonella typhi ty2 vi polysaccharide antigen The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Capromab pendetide. Approved Salmonella typhi ty21a live antigen The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Capromab pendetide. Approved Secoisolariciresinol Secoisolariciresinol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Investigational SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Capromab pendetide. Investigational Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Capromab pendetide. Investigational TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Capromab pendetide. Investigational Tibolone Tibolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Investigational Tixocortol Tixocortol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Withdrawn Triamcinolone Triamcinolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Triptorelin Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved, Vet Approved Ulobetasol Ulobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Varicella Zoster Vaccine (Live/Attenuated) The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Capromab pendetide. Approved Yellow Fever Vaccine The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Capromab pendetide. Approved, Investigational Zeranol Zeranol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Vet Approved - Food Interactions
- Not Available
References
- General References
- External Links
- PubChem Substance
- 46506263
- ChEMBL
- CHEMBL2108285
- Therapeutic Targets Database
- DAP001049
- PharmGKB
- PA164745489
- Wikipedia
- Indium_(111In)_capromab_pendetide
- ATC Codes
- V09IB04 — Indium (111in) capromab pendetide
- FDA label
- Download (1.65 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Diagnostic Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- EUSA Pharma Inc.
- Dosage forms
Form Route Strength Kit - Prices
Unit description Cost Unit Prostascint kit 1584.0USD kit DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C (FAB fragment), 71 °C (whole mAb) Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Other/unknown
- General Function
- Tetrahydrofolyl-poly(glutamate) polymer binding
- Specific Function
- Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of fola...
- Gene Name
- FOLH1
- Uniprot ID
- Q04609
- Uniprot Name
- Glutamate carboxypeptidase 2
- Molecular Weight
- 84330.015 Da
References
- Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [PubMed:11016653]
- Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [PubMed:15882479]
- Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [PubMed:9508077]
- Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [PubMed:9792131]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 01:52